Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer

Rhea-AI Summary

Terumo Blood and Cell Technologies (Terumo BCT) has appointed Patrick Daly as its new Chief Business Officer. With over 30 years of healthcare industry experience, Daly joins from IQVIA where he built the MedTech Global Data franchise.

Prior to IQVIA, Daly served as President and CEO of Cohera Medical and currently maintains a position as independent Board Director for BioStem Technologies. His extensive career includes senior leadership roles at Johnson & Johnson in strategic marketing, sales, and business development. Daly holds a Bachelor of Science in Foreign Area Studies from West Point.

According to CEO Antoinette Gawin, Daly's expertise in capital acquisition, strategic partnerships, and data monetization positions him to integrate offerings and drive innovation. The appointment aligns with Terumo BCT's ambitions for double-digit growth and its mission to address global healthcare challenges through enhanced disease research, therapeutic development, and blood safety initiatives.

Daly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth

LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience, both domestically and internationally. Most recently, he built the MedTech Global Data franchise at IQVIA, a provider of technology solutions to the life sciences industry.

Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson & Johnson. He earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point.

"Patrick's experience acquiring capital and building strategic partnerships complements his experience monetizing data and solutions. This uniquely positions him to integrate our offerings and drive innovation across our business models and go-to-market strategies," said Antoinette Gawin, President and Chief Executive Officer of Terumo BCT. "His diverse experience will help accelerate our ambitions for double-digit growth."

"It is a great moment to join Terumo BCT as it continues executing its long-term vision for growth and to meet patients' unmet needs globally," said Daly. "I am focused on ensuring our full portfolio, connected with data, software and services, will play a growing role in helping our customers solve healthcare's toughest challenges, while advancing disease research, therapeutic development and improved access to safe blood worldwide."

About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 150 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, eight manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-blood-and-cell-technologies-names-patrick-daly-as-chief-business-officer-302430575.html

SOURCE Terumo Blood and Cell Technologies

FAQ

What is Patrick Daly's new role at Terumo BCT (TRUMY)?

Patrick Daly has been appointed as Chief Business Officer at Terumo Blood and Cell Technologies (Terumo BCT) in April 2025.

What is Patrick Daly's professional background before joining TRUMY?

Daly has 30+ years of healthcare industry experience, previously built IQVIA's MedTech Global Data franchise, served as CEO of Cohera Medical, and held senior leadership positions at Johnson & Johnson.

What are Terumo BCT's (TRUMY) growth targets under the new leadership?

Terumo BCT is targeting double-digit growth, with Daly's appointment aimed at integrating offerings and driving innovation across business models.

How will Patrick Daly contribute to Terumo BCT's (TRUMY) business strategy?

Daly will focus on integrating the company's portfolio with data, software, and services to help customers address healthcare challenges and improve global blood safety.

What educational background does the new TRUMY Chief Business Officer have?

Patrick Daly holds a Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point.